Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime
Sponsored by Lund University Hospital
About this trial
Last updated 4 years ago
Study ID
MKM-1
Status
Completed
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 5 years ago
What is this trial about?
Oxaliplatin is a cytotoxic platinum compound and is one of the chemotherapeutic agent
used in advanced colorectal cancer. It is used combined with Fluorouracil (5 FU) and
Leucovorin. The main and most suffering side effect of oxaliplatin is polyneuropathy.
Oxaliplatin-induced polyneuropathy (OIPN) can be acute and/or chronic neurotoxicity.
The early detection of the neurotoxicity and changing the medication dose and/or schedule
can prevent its development. It has been used different neurotoxicity scales in grading
OIPN. In this study the investigators try to investigate whether the evaluation of the
vibrotactile perception VTP, by using a multi frequency tactilometry in a patients hand
and foot is a good indicator and superior to the standard of care to detect the
underlying OIPN in patients undergoing adjuvant chemotherapy treatment with FOLFOX, FLOX
or XELOX regime.
What are the participation requirements?
Inclusion Criteria
- Age ≥ 18 years
- Signed written informed consent.
- Fulfils the indication of the treatment with 3-6 months oxaliplatin combined adjuvant chemotherapy.
- Polyneuropathy grade according to CTCAE before treatment start ≤ 2.
- Performance status according to WHO ≤ 1.
Exclusion Criteria
- Age < 18 years.
- The patient does not consent to the examination
- Polyneuropathy grade according to CTCAE before treatment start >2.
- Performance status according to WHO >1.